Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Aurobindo Pharma

Aurobindo Pharma

BSE: 524804|NSE: AUROPHARMA|ISIN: INE406A01037|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jul 28, 16:01
724.05
-14.85 (-2.01%)
VOLUME 173,123
LIVE
NSE
Jul 28, 15:59
723.90
-14.85 (-2.01%)
VOLUME 2,172,136
News on Aurobindo Pharma
Select Year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Buy Aurobindo Pharma; target of Rs 850: Axis Direct

5.01 pm | 27 Jul 2017 |  Source: Moneycontrol.com

Axis Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 850 in its research report dated July 24,...

Buy Aurobindo Pharma, State Bank of India, Arvind: Sudarshan Sukhani 

2.46 pm | 27 Jul 2017 |  Source: CNBC-TV18

Sudarshan Sukhani of s2analytics.com recommends buying Aurobindo Pharma, State Bank of India and Arvind....

Aurobindo Pharma's Q1 results on August 9, 2017

12.21 pm | 27 Jul 2017 |  Source: Moneycontrol.com

A meeting of the Board of Directors of the Company will be held on Wednesday 9th August, 2017 to consider and approve, inter alia, the Un-audited Fina...

Nifty hits magical number of 10,000: 'Picture abhi baki hai' say D-Street veterans 

9.53 am | 25 Jul 2017 |  Source: Moneycontrol.com

Political stability, along with stable macros and a strong currency are some of the factors which have made India as one of the sought out destination...

Buy Aurobindo Pharma; target of Rs 850: Motilal Oswal

3.29 pm | 20 Jul 2017 |  Source: Moneycontrol.com

Motilal Oswal recommended buy rating on Aurobindo Pharma with a target price of Rs 850 in its research report dated July 19, 2017....

Aurobindo Pharma gets USFDA nod to market kidney ailment drug

11.45 am | 19 Jul 2017 |  Source: PTI

"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg," Aurobind...

Expect EPS upgrades & valuation rerating for Aurobindo: Surajit Pal 

11.01 am | 19 Jul 2017 |  Source: CNBC-TV18

Aurobindo Pharma has gotten the United States Foods and Drug Administration (USFDA) approval for a generic drug that treats a chronic kidney disease. ...

Buy RCF, Sintex Industries; sell Escorts, IRB Infra, VIP Industries: Ashwani Gujral 

9.21 am | 19 Jul 2017 |  Source: CNBC-TV18

Ashwani Gujral of ashwanigujral.com recommends buying Rashtriya Chemicals & Fertilizers and Sintex Industries and advises selling Escorts, IRB Inf...

Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate tablets

9.05 am | 19 Jul 2017 |  Source: Moneycontrol.com

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg. Sevelam...

Buy, Sell, Hold: Analysts are tracking these 2 stocks today. Do you own them?

8.40 am | 19 Jul 2017 |  Source: CNBC-TV18

HUL and Aurobindo Pharma are on the radar of investors on Wednesday....

HDFC Securities expects Aurobindo Pharma to touch Rs 760 

4.46 pm | 14 Jul 2017 |  Source: CNBC-TV18

Aurobindo Pharma gains ahead of US Food and Drug Administration (US FDA) target action date for Renvela generic. In an interview to CNBC-TV18, Amey Ch...

Nifty at record high with Mount 10k in sight: 4 stocks to buy today: Prakash Gaba 

8.02 am | 14 Jul 2017 |  Source: Moneycontrol.com

According to Prakash Gaba of prakashgaba.com, crucial support to watch would be 9850 and the resistance is at 9916-9969. On the other hand, Bank Nifty...

Buy Aurobindo Pharma, Welspun India; sell Britannia Industries: Ashwani Gujral 

2.51 pm | 07 Jul 2017 |  Source: CNBC-TV18

Ashwani Gujral of ashwanigujral.com is of the view that one may buy Aurobindo Pharma and Welspun India and can sell Britannia Industries....

Retail investors should be cautious while investing in market: Rahul Arora 

2.44 pm | 04 Jul 2017 |  Source: CNBC-TV18

In an interview to CNBC-TV18, Rahul Arora, CEO at Nirmal Bang Institutional Equities shared his readings and outlook on the market and specific stocks...

Here are some fundamental trading ideas from SP Tulsian 

5.09 pm | 30 Jun 2017 |  Source: CNBC-TV18

In an interview to CNBC-TV18, SP Tulsian of sptulsian.com shared his readings and outlook on market and specific stocks....

Buy Aurobindo Pharma, Apollo Tyres; sell Pidilite Industries: Ashwani Gujral 

3.26 pm | 28 Jun 2017 |  Source: CNBC-TV18

Ashwani Gujral of ashwanigujral.com is of the view that one can buy Aurobindo Pharma and Apollo Tyres and can sell Pidilite Industries....

Aurobindo Pharma up 3% on zero observations for Hyderabad unit; Jefferies retains buy

1.14 pm | 27 Jun 2017 |  Source: Moneycontrol.com

Aurobindo Pharma has, in Q1FY18 YTD, launched more 7 products (against 5 in Q4FY17) including 3 complex products - Meropenem, Strattera and Renvela su...

Sell Hindalco, Arvind; buy Britannia Industries, Mindtree: Sudarshan Sukhani 

11.08 am | 27 Jun 2017 |  Source: CNBC-TV18

According to Sudarshan Sukhani of s2analytics.com, one can sell Hindalco Industries and Arvind and can buy Britannia Industries and Mindtree....

Buy Reliance Capital, Rain Industries, NBCC; sell Bajaj Finserv below Rs 4080: Mitessh Thakkar 

10.36 am | 27 Jun 2017 |  Source: CNBC-TV18

Mitessh Thakkar of miteshthacker.com is of the view that one can buy Reliance Capital, NBCC and Rain Industries and can sell Bajaj Finserv below Rs 40...

Buy, Sell, Hold: 3 stocks and 1 sector on analysts' radar today

9.43 am | 27 Jun 2017 |  Source: CNBC-TV18

Morgan Stanley feels Vedanta's favorable commodity exposure and robust volume growth bode well for earnings and cash flows....

1 2 3 4 5
Quick Links for Aurobindo Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.